Study wrapper · #786
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Editor's note
This US cost-effectiveness simulation compared tirzepatide against semaglutide (both at maximum tolerated dose) for obesity or overweight, using head-to-head SURMOUNT-5 trial data as its clinical engine. Researchers reported the model estimated tirzepatide to be both less costly (about $41,688 saved per patient, societal perspective) and more effective on modelled outcomes (0.506 QALYs gained), projecting fewer future cases of type 2 diabetes and cardiovascular disease. This is an economic model, not new clinical evidence: outputs depend on SURMOUNT-5's weight-loss advantage for tirzepatide plus many pricing and progression assumptions, and the sensitivity analyses matter for interpretation. It usefully frames a real decision, the two leading agents head to head, but the QALY and cost figures are projections, not observed outcomes, and the disclosed sponsorship context of such models warrants a careful read.
Plain-language abstract
This study did not test patients directly; instead it used a computer model to compare the long-term costs and health results of two weight-loss medicines, tirzepatide and semaglutide, both at their highest tolerated dose. The model was built on results from SURMOUNT-5, a trial that compared the two drugs head-to-head. It projected that tirzepatide would save money (about $41,688 per patient over a lifetime) while also producing better modelled health outcomes, including fewer future cases of type 2 diabetes and heart disease. Because this is a projection based on assumptions about prices and how disease progresses, the numbers are estimates rather than measured results, and they lean on tirzepatide's larger weight loss in the underlying trial. It is a useful way to frame the choice between the two drugs, but should be read as modelling, not proof.